Ref: JSTL/BOD/BSE/2020-21/Jan21 **Date: January 27, 2021**

To,
The Manager
BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

Dear Sir/Madam,

Sub: Outcome of board meeting under Regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: Jeevan Scientific Technology Limited (Scrip code: 538837)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Jeevan Scientific Technology Limited held on Wednesday, the 27th day of January, 2021 at 11.30 A.M. at the registered office of the Company the following were duly considered and approved:

1. Un-audited Financial Results of the company as per Ind AS for the quarter ended December 31, 2020.
2. Limited review report of auditors thereon.
3. Evaluation of the Board as a whole and its committees.

The meeting of the Board of Directors commenced at 11.30 A.M and concluded at 3.00 P.M

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Jeevan Scientific Technology Limited

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

K. Krishna Kishore
Managing Director and CFO
DIN: (00876539)

Encl: Limited Review Report and Un-Audited Financials for quarter ended December 31, 2020.

Ref: JSTL/BOD/BSE/2020-21/Jan21 **Date: January 27, 2021**

To,
The Manager
BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.
BSE Scrip Code: 538837

Dear Sir/Madam,

Sub: Limited Review report of the Stand Alone and Consolidated Un-Audited Financial Results for the Quarter Ended 31st December, 2020.

We are herewith enclosing the Limited Review Report issued by our Statutory Auditors relating to the Stand Alone and Consolidated Un-Audited Financial Results for the Quarter Ended 31st December, 2020 which were taken on record by the Board of Directors at their Meeting held on the 27th January, 2021.

This is for your information and records,

Thanking you,

Yours truly,
For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)

Encl. As above

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

Independent Auditor's Review Report

Review Report to
The Board of Directors,
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the company") for the quarter and nine months ended **31st December, 2020** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.

b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.

c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S

RAJESH NUKAVARAPU
Digitally signed by RAJESH NUKAVARAPU

(CA. N. RAJESH)
PARTNER
M.No: 223169

UDIN # 21223169AAAAAQ1201
Place: Hyderabad
Date: 27.01.2021

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

Independent Auditor's Consolidated Review Report

Review Report to
The Board of Directors,
Jeevan Scientific Technology Limited

a) We have reviewed the accompanying statement of unaudited Consolidated financial results of **M/s. Jeevan Scientific Technology Limited** ("the company") for the quarter and months ended ended **31st December, 2020** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.

b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.

c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S
RAJESH NUKAVARAPU
Digitally signed by RAJESH NUKAVARAPU
(CA. N. RAJESH)
Partner
Mem No. 223169

Place: Hyderabad
Date: 27.01.2021
UDIN # 21223169AAAAAR9313

Ref: JSTL/BOD/BSE/2020-21/Jan21 **Date: January 27, 2021**

To,
The Manager
BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.
BSE Scrip Code: 538837

Dear Sir/Madam,

Sub: Copy of Stand Alone and Consolidated Un-Audited Financial Results for the Quarter Ended 31st December, 2020.

Please find enclosed herewith a Copy of Stand Alone and Consolidated Un-Audited Financial Results for the Quarter Ended 31st December, 2020 which were taken on record by the Board of Directors at their Meeting held on 27th January, 2021.

This is for your information and records,

Thanking you,

Yours truly,

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)

Encl. As above

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
1	**Income**						
	(a) Revenue From Operations	1442.30	996.57	726.55	2783.47	1500.06	2056.74
	(b) Other Income	23.34	29.78	37.32	84.57	90.98	156.30
	(c) Unbilled Revenue	0.00	86.80	-	53.00	-	95.80
	Total income	**1,465.64**	**1,113.15**	**763.87**	**2,921.04**	**1,591.04**	**2,308.84**
2	**Expenses**						
	(a) Cost of Material Consumed	87.49	59.13	40.97	157.40	117.73	156.89
	(b) Purchase of stock-in-trade	-	-	-	0.00	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(89.00)	(90.00)	-	(176.60)	-	(70.40)
	(d) Employee benefit expense	246.94	228.39	209.95	642.30	614.36	820.86
	(e) Finance Cost	40.67	53.07	55.98	138.71	175.39	226.82
	(f) Depreciation and Amortisation expense	99.29	99.40	99.77	297.20	297.74	390.78
	(g) Other Expenses	357.64	391.61	281.52	890.63	736.13	1021.67
	Total Expenses	**743.03**	**741.60**	**688.19**	**1,949.64**	**1,941.35**	**2,546.62**
3	Profit before exceptional items and Tax	722.61	371.55	75.68	971.40	-350.31	-237.78
4	Add(+)/Less(-) Exceptional items	-	-	-	-	-	739.24
5	Profit/ (Loss) before Tax	722.61	371.55	75.68	971.40	-350.31	-977.02
6	Tax Expenses	121.97	-98.49	-23.05	192.17	68.99	195.55
7	Profit(Loss) for the Period from Continuing Operations	600.64	273.06	52.63	779.23	-281.32	-781.47
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-	-
			-	-			
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	600.64	273.06	52.63	779.23	-281.32	-781.47
12	Other Comprehensive Income						
	A (i) Items that will not be reclassfied to profit or loss	-0.28	-1.07	0.98	-0.83	-6.77	-2.43
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	600.36	271.99	53.61	778.40	-288.09	-783.90
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve	-	-	-			962.83
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	3.92	1.78	0.35	5.09	-1.88	-5.12
	b) Diluted (Amount in Rupees)	3.92	1.78	0.35	5.09	-1.88	-5.12
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)	-	-	-	-	-	-
	b) Diluted (Amount in Rupees)	-	-	-	-	-	-
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	3.92	1.78	0.35	5.09	-1.88	-5.12
	b) Diluted (Amount in Rupees)	3.92	1.78	0.35	5.09	-1.88	-5.12

Notes to the Standalone Un Audited Financial Results

1 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015

2 The above results have been reviewed by the Audit Committee at its meeting held on 27.01.2021 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.

3 During the year Company is operating in only one segment i.e., Clinical Research Services

4 The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non -financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes in future economic conditions.

5 Figures for the previous periods have been rearranged whereever necessary.

Place:Hyderabad
Date:27.01.2021

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

K. Krishna Kishore
Vice Chairman & Managing Director

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.

CONSOLIDATED UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
1	**Income**						
	(a) Revenue From Operations	1578.73	1138.16	842.69	3250.31	1686.40	2394.09
	(b) Other Income	23.34	29.88	37.70	84.78	92.09	157.60
	(c) Unbilled Revenue	0.00	86.80	-	53.00	-	95.80
	Total income	**1,602.07**	**1,254.84**	**880.39**	**3,388.09**	**1,778.49**	**2,647.49**
2	**Expenses**						
	(a) Cost of Material Consumed	87.49	59.13	40.97	157.4	117.73	156.89
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-89.00	-90.00	-	-176.60	-	-70.40
	(d) Employee benefit expense	328.24	312.14	293.17	893.01	750.78	1044.52
	(e) Finance Cost	58.59	71.76	73.85	194.15	203.82	273.13
	(f) Depreciation and Amortisation expense	99.62	99.73	100.10	298.19	298.69	392.05
	(g) Other Expenses	422.17	428.99	310.69	1040.01	785.28	1166.37
	Total Expenses	**907.11**	**881.75**	**818.78**	**2,406.16**	**2,156.30**	**2,962.56**
3	Profit before exceptional items and Tax	694.96	373.09	61.61	981.93	-377.81	-315.07
4	Add(+)/Less(-) Exceptional items	-	-	-		-	739.24
5	Profit/ (Loss) before Tax	694.96	373.09	61.61	981.93	-377.81	-1,054.31
6	Tax Expenses	121.97	-98.49	-23.05	192.17	68.99	195.71
7	Profit(Loss) for the Period from Continuing Operations	572.99	274.60	38.56	789.76	-308.82	-858.60
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	572.99	274.60	38.56	789.76	-308.82	-858.60
12	Other Comprehensive Income						
	A (i) Items that will not be reclassfied to profit or loss	-0.28	-1.07	0.98	-0.83	-6.77	-2.43
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	572.71	273.53	39.54	788.93	-315.59	-861.03
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve						792.14
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63
	b) Diluted (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)						-
	b) Diluted (Amount in Rupees)						-
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63
	b) Diluted (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63

Notes to the Consolidated Un Audited Financial Results

1 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015

2 The above results have been reviewed by the Audit Committee at its meeting held on 27.01.2021 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.

3 The Group currently has two segments (i) clinical research services and (ii) Information technology services.

4 The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non -financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes in future economic conditions.

5 Figures for the previous periods have been rearranged whereever necessary.

6 The above consolidated financial results include the Un Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

Place:Hyderabad
Date: 27.01.2021



SEGMENT-WISE REVENUE,RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020

Rupees in Lakhs

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
	SEGMENT REVENUE: (Net Sales / Income from Operations)						
	a) Clinical Research Services	1,465.64	1,113.15	763.87	2,921.04	1,591.04	2,308.84
	b) Information Technology Services	136.43	141.69	116.52	467.05	187.45	338.65
	Total:	**1,602.07**	**1,254.84**	**880.39**	**3,388.09**	**1,778.49**	**2,647.49**
	LESS: Inter Segment revenue	-			-	-	-
	Net Sales/income from Operations.	**1,602.07**	**1,254.84**	**880.39**	**3,388.09**	**1,778.49**	**2,647.49**
	SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST						
	a) Clinical Research Services	763.28	424.62	131.66	1,110.11	-174.92	-10.96
	b) Information Technology Services	(9.73)	20.23	3.80	65.97	0.93	-30.98
	Total:	**753.55**	**444.85**	**135.46**	**1,176.08**	**-173.99**	**-41.94**
	LESS:						
	i) Interest	58.59	71.76	73.85	194.15	203.82	273.13
	ii) Other Un-Allocable Expenditure	-	-	-	-	-	-
	iii) Un-Allocable Income	-	-	-	-	-	-
	TOTAL PROFIT /(-LOSS) BEFORE TAX	**694.96**	**373.09**	**61.61**	**981.93**	**-377.81**	**-315.07**

Place:Hyderabad
Date:27.01.2021

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

K. Krishna Kishore
Vice Chairman & Managing Director

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD